Jun 16, 2020

VivaGel® BV launched in central and eastern European countries

VivaGel® BV launched in central and eastern European countries
  • VivaGel® BV has been launched in the Central and Eastern European region
  • VivaGel® BV is now available Over-The-Counter in Western and Eastern European countries (including the UK)
  • Mundipharma expects to launch VivaGel® BV in additional countries in Europe throughout the year ahead
  • Further launches are also planned in other Mundipharma territories, including in Asia, and regulatory activities continue in multiple regions

Melbourne, Australia; 16 June 2020: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that VivaGel® BV has been launched in Central and Eastern European (CEE) region. This launch follows European launches in Germany, UK and several other European countries.

VivaGel® BV is available Over-The-Counter (OTC) in the CEE, without the need to see a doctor or obtain a prescription. The CEE represents a valuable commercial opportunity for VivaGel® BV with access to more than 45 million women and Mundipharma continues to roll-out the product in the region.

Dr Jackie Fairley, Starpharma CEO, commented: “We are excited to see VivaGel® BV being rolled-out through Europe and the marketing and launch activities being undertaken by Mundipharma. It’s been particularly pleasing to have both teams collaborating so successfully on launch and regulatory activities, and we look forward to supporting Mundipharma in its preparations for upcoming launches.”

Raman Singh, Mundipharma CEO, commented: “VivaGel® BV is fast-becoming a trusted brand, based on its quality and effectiveness as a treatment for BV. We are delighted to be able to deliver this product to women in eastern and central Europe through our extensive marketing and distribution network.”

About VivaGel® BV

VivaGel® BV is a novel, non-antibiotic therapy for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV. BV is the most common vaginal condition worldwide and twice as common as thrush. One in three women will experience BV and half of these women will have recurrent BV. VivaGel® BV is an Australian innovation – invented, fully developed and taken through to commercialisation by Starpharma.

BV is a troublesome and often recurrent condition that causes unpleasant vaginal odour and discharge symptoms that have significant social impact for women. BV has also been associated with a range of other serious reproductive health-related medical problems.

VivaGel® BV is available for sale under the brand names Betafem® BV Gel (UK), BETADINE BVTM Gel (Europe), BETADINETM BV Gel (Asia) and Fleurstat BVgel (Australia).

Download ASX Announcement: VivaGel® BV launched in central and eastern European countries (pdf, 59kb)

 This contains certain forward-looking statements.